KR20180089531A - Tlr 저해성 올리고뉴클레오티드 및 그의 용도 - Google Patents

Tlr 저해성 올리고뉴클레오티드 및 그의 용도 Download PDF

Info

Publication number
KR20180089531A
KR20180089531A KR1020187021100A KR20187021100A KR20180089531A KR 20180089531 A KR20180089531 A KR 20180089531A KR 1020187021100 A KR1020187021100 A KR 1020187021100A KR 20187021100 A KR20187021100 A KR 20187021100A KR 20180089531 A KR20180089531 A KR 20180089531A
Authority
KR
South Korea
Prior art keywords
modified
oligonucleotide
oligonucleotides
disease
mediated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020187021100A
Other languages
English (en)
Korean (ko)
Inventor
에이지 에사시
고지 이시다
다쿠미 호소자와
메구미 오쿠야마
아유미 고타키
Original Assignee
에스비아이 바이오테크 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에스비아이 바이오테크 가부시키가이샤 filed Critical 에스비아이 바이오테크 가부시키가이샤
Publication of KR20180089531A publication Critical patent/KR20180089531A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/17—Immunomodulatory nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/50—Methods for regulating/modulating their activity
    • C12N2320/51—Methods for regulating/modulating their activity modulating the chemical stability, e.g. nuclease-resistance
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/50—Methods for regulating/modulating their activity
    • C12N2320/53—Methods for regulating/modulating their activity reducing unwanted side-effects

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020187021100A 2015-12-25 2016-12-22 Tlr 저해성 올리고뉴클레오티드 및 그의 용도 Withdrawn KR20180089531A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2015255008 2015-12-25
JPJP-P-2015-255008 2015-12-25
PCT/JP2016/088418 WO2017111045A1 (en) 2015-12-25 2016-12-22 Tlr inhibitory oligonucleotides and their use

Publications (1)

Publication Number Publication Date
KR20180089531A true KR20180089531A (ko) 2018-08-08

Family

ID=59090457

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020187021100A Withdrawn KR20180089531A (ko) 2015-12-25 2016-12-22 Tlr 저해성 올리고뉴클레오티드 및 그의 용도

Country Status (9)

Country Link
US (1) US10806749B2 (enExample)
EP (1) EP3394263B1 (enExample)
JP (1) JP7079495B2 (enExample)
KR (1) KR20180089531A (enExample)
CN (1) CN108431228A (enExample)
AU (1) AU2016375543A1 (enExample)
CA (1) CA3009154A1 (enExample)
IL (1) IL260193A (enExample)
WO (1) WO2017111045A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3468605A4 (en) 2016-06-08 2020-01-08 President and Fellows of Harvard College MANIPULATED VIRAL VECTOR TO REDUCE INDUCTION OF IGNITION AND IMMUNE REACTIONS
US10350307B2 (en) * 2017-09-18 2019-07-16 General Electric Company In vivo RNA or protein expression using double-stranded concatemeric DNA including phosphorothioated nucleotides
AU2018364542A1 (en) 2017-11-08 2020-04-16 President And Fellows Of Harvard College Compositions and methods for inhibiting viral vector-induced inflammatory responses
CN109266732A (zh) * 2018-09-13 2019-01-25 中山大学附属第医院 TLR7和TLR8作为IgA肾病预防治疗靶点的应用及TLR7的抑制剂及其应用
CN114569722B (zh) * 2022-03-07 2022-11-22 广州市妇女儿童医疗中心 抑制血小板焦亡的试剂在制备预防和/或治疗脓毒症的药物中的用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5011520A (enExample) 1973-05-31 1975-02-06
EP2154144A1 (en) 2008-08-06 2010-02-17 Changchun Huapu Biotechnology Co., Ltd. Oligonucleotides and use thereof
US8030289B2 (en) 2008-08-06 2011-10-04 Changchun Huapu Biotechnology Co., Ltd. Oligonucleotide and use thereof
WO2014082254A1 (en) 2012-11-29 2014-06-05 Changchun Huapu Biotechnology Co., Ltd Inhibitory oligonucleotide and use thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003275776B2 (en) * 2002-11-08 2009-06-18 Jingang Medicine (Australia) Pty Ltd A method for optimising gene expression using synonymous codon optimisation
IL161579A0 (en) * 2004-04-22 2004-09-27 Mor Research Applic Ltd ANTISENSE OLIGONUCLEOTIDES AGAINST cPLA2, COMPOSITIONS AND USES THEREOF
ATE541928T1 (de) * 2005-03-31 2012-02-15 Calando Pharmaceuticals Inc Inhibitoren der untereinheit 2 der ribonukleotidreduktase und ihre verwendungen
JP5011520B2 (ja) 2005-08-12 2012-08-29 国立大学法人 長崎大学 新規ヒト形質細胞様樹状細胞株
CN101696434A (zh) * 2009-10-27 2010-04-21 中国科学院过程工程研究所 β-聚苹果酸发酵新工艺
US20170240896A1 (en) * 2014-02-07 2017-08-24 Sbi Biotech, Co., Ltd. Inhibitory Oligonucleotides for Treating Tumors

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5011520A (enExample) 1973-05-31 1975-02-06
EP2154144A1 (en) 2008-08-06 2010-02-17 Changchun Huapu Biotechnology Co., Ltd. Oligonucleotides and use thereof
US8030289B2 (en) 2008-08-06 2011-10-04 Changchun Huapu Biotechnology Co., Ltd. Oligonucleotide and use thereof
WO2014082254A1 (en) 2012-11-29 2014-06-05 Changchun Huapu Biotechnology Co., Ltd Inhibitory oligonucleotide and use thereof

Non-Patent Citations (46)

* Cited by examiner, † Cited by third party
Title
Baldwin (Jr) et al., Annu Rev Immunol, 1996, 14, 649-683
Barrat, et al., J Exp Med, 2005, 202, 1131-9
Boule et al., J Exp Med, 2004, 199, 1631-40
Burdick et al., Nuc Acid Res, 2014, 42, 4882-4891
Christensen et al., Immunity, 2006, 25, 417-28
Davidson, Engl J Med, 2001, 345, 340-350
Deleavey et al., Chemistry & Biology, 19, 937-954
Delgado-Vega et al., Arthritis Research & Therapy 2010, 12/S2
Espat et al., J Surg Res, 1995, 59, 153-8
Freier et al., Nuc Acid Res, 1997, 25, 4429-4443
Gambuzza et al., J Neuroimmunol, 2011, 239, 1-12
Gilliet et al., Nat. Rev. Immunol. 2008, 8, 594-606
Goldsby et al., Immunology, Fifth Edition, 2003, W.H. FREEMAN AND COMPANY
Guidance for Industry, Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers, U.S. Department of Health and Human Services Food and Drug Administration, Center for Drug Evaluation and Research (CDER), July 2005
Hagedorn et al., Nuc Acid Ther, 2013, 23, 302-310
Hatemi et al., Clin Exp Rheumatol, 2015, 33 (6 Suppl 94), 3-14
Henry et al., Toxicol Pathol, 1999, 28, 95-100
Ito et al., Blood, 2006, 107, 2423-2431
Klinman, Nat. Rev. Immunol, 2004, 4, 249-258
Krieg, Nature Reviews Drug Discovery, 2006, 5, 471-484
Kuwahara et al., Molecules, 2010, 15, 5423-5444
Leadbetter et al., Nature, 2002, 416, 603-7
Liew et al., Nature Reviews Immunology, 2005, 5, 446-458
Liu et al., Itch: Mechanisms and Treatment, Carstens E, Akiyama T, editors, 2014, CRC Press/Taylor & Francis
Liu et al., Neurosci Bull, 2012, 28, 131-44
Maeda et al., Int J Hematol., 2005, 81, 148-54
Marshall et al., Infect Immun, 1998, 66, 1325-33
Miyazawa et al., Am J Pathol 1998, 152, 793-803
Monteith et al., Toxicol Pathol, 1999, 27, 307-317
Mutisya et al., Nucleic Acids Research, 2014, 42, 6542-6551
Neurath et al., Ann NY Acad Sci, 1998, 859, 149-159
Patel et al., Mol Cell Neurosci, 2014, 63, 38-48
Peter et al., Immunology, 2008, 123, 118-28
Schottelius et al., J Biol Chem 1999, 274, 31868-31874
Sharma et al., Med. Chem. Commun. 2014, 5, 1454-1471
Slifka et al., J Mol Med. 2000, 78, 74-80
Smith, Curr Opin Nehrol Hypertens, 2009, 18, 189
Stein et al., Nuc Acid Res, 1988, 16, 3209-3221
Sun et al., Clin Immunol, 2010, 134, 262-276
Tak et al., J Clin Invest, 2001, 107, 7-11
Tang et al., Respirology, 2015, Oct 18. doi: 10.1111/resp.12657. [Epub ahead of print]
The Gilmore Lab, Boston University Biology [online, retrieved on Nov 4th, 2015] Retrieved from Internet: <URL: http://www.bu.edu/nf-kb/physiological-mediators/diseases/>
The Writing Committee of the World Health Organization (WHO) Consultation on Human Influenza A/H5, N Engl J Med, 2005, 353, 1374-85
Wang et al., Am J Emerg Med, 2008, 26, 711-5
Wellmann, et al., Proc Natl Acad Sci USA, 2005, 102, 9258-63
Zhang et al., International Immunopharmacol, 2012, 446-453

Also Published As

Publication number Publication date
IL260193A (en) 2018-07-31
JP2019500873A (ja) 2019-01-17
AU2016375543A1 (en) 2018-06-28
CA3009154A1 (en) 2017-06-29
EP3394263A1 (en) 2018-10-31
EP3394263A4 (en) 2019-08-21
CN108431228A (zh) 2018-08-21
JP7079495B2 (ja) 2022-06-02
US20190008888A1 (en) 2019-01-10
US10806749B2 (en) 2020-10-20
EP3394263B1 (en) 2025-02-26
WO2017111045A1 (en) 2017-06-29

Similar Documents

Publication Publication Date Title
US8470342B2 (en) Methods of altering an immune response induced by CpG oligodeoxynucleotides
KR102027023B1 (ko) 저해성 올리고뉴클레오티드 및 그의 용도
EP2754714A1 (en) Inhibitory oligonucleotides and their use in therapy
CN102256594A (zh) 通过反义寡核苷酸来调制toll样受体8表达
JP7079495B2 (ja) Ｔｌｒ阻害性オリゴヌクレオチドおよびそれらの使用
CN102245187A (zh) 通过反义寡核苷酸来调制toll样受体3表达
US8030289B2 (en) Oligonucleotide and use thereof
KR20110081337A (ko) 안티센스 올리고누클레오티드에 의한 ｔｏｌｌ―유사 수용체 4 발현의 조절
JP2017506232A (ja) 腫瘍を治療するための阻害性オリゴヌクレオチド
EP2154144B1 (en) Oligonucleotides and use thereof
HK1133043A (en) Oligoribonucleotides and uses thereof

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20180720

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid